Owlet, Inc.
NYSE:OWLTMedical - Devices
+$0.46 today
- Market cap
- $107.24M
- Beta
- 1.86
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$12.67
Volume 0.64M
Average 0.24M
OWLT Operating Cash Flow
Cash generated by the company's core business operations during the period.
Owlet, Inc.NYSE: OWLT
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $5M (cash outflow) fell 15.6% year over year, ahead of the -28.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 1006.2% from the prior quarter. Over 3 fiscal years it compounded at -49.0% a year.
Context
- Operating cash flow amounted to 10.2% of revenue in FY2025, down 4.1 pp from a year earlier.
- Operating cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -15.6% holds above the trailing-twelve-month pace of -28.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (10.8M) USD
- Year-over-year change
- +3.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.8M) | +3.6% |
| FY2024 | 2024-12-31 | (11.21M) | +52.4% |
| FY2023 | 2023-12-31 | (23.53M) | +71.1% |
| FY2022 | 2022-12-31 | (81.38M) | -100.7% |
| FY2021 | 2021-12-31 | (40.56M) | — |
Operating Cash Flow vs competitors
How OWLT compares with its peers on the latest reported figures
- OWLT's LTM Mar 2026 operating cash flow of $9.87M is the 9th largest of the 10 companies compared; the peer median is $37.42M.
- Its year-over-year change of -28.4% is the lowest of 10, against a peer median of +9.7%.
- Operating cash flow amounts to 9.2% of revenue for OWLT, versus a peer median of 105.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $84.99M | +26.5% | +38.3% | 4591.8% |
| LTM Mar 2026 | $73.64M | +46.6% | +19.8% | — | |
| LTM Mar 2026 | $46.12M | +4.8% | +16.1% | 898.3% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $38.48M | +9.7% | +18.5% | — |
| LTM Mar 2026 | $37.42M | -12.5% | +3.9% | 7127.0% | |
| LTM Mar 2026 | $36.18M | -4.0% | -19.0% | 105.2% | |
| LTM Mar 2026 | $28.17M | -10.5% | +32.5% | 87.2% | |
| LTM Mar 2026 | $12.16M | +211.4% | -0.1% | 21.1% | |
| LTM Mar 2026 | $9.87M | -28.4% | -49.0% | 9.2% | |
| LTM Mar 2026 | $6.47M | +19.9% | +36.4% | 5.6% | |
| Peer median (excluding OWLT) | $37.42M | +9.7% | +18.5% | 105.2% | |
Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.7M) | (79.34M) | (32.9M) | (12.54M) | (38.46M) |
| Depreciation & Amortization | 1.13M | 2.67M | 2.21M | 1.38M | 590K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.26M | 12.86M | 9.93M | 8.63M | 9.35M |
| Change in Working Capital | 9.45M | (15.2M) | (4.82M) | (2.52M) | (10.71M) |
| Accounts Receivables | (144K) | (8.5M) | 965K | 2.03M | (10.97M) |
| Inventory | (11.65M) | (1.18M) | 12.12M | (4.14M) | (4.93M) |
| Accounts Payables | 32.12M | (10.72M) | (19.5M) | 1.32M | 5.43M |
| Other Working Capital | (10.87M) | 5.2M | 1.6M | (1.74M) | (236K) |
| Other Non-Cash Items | 16.3M | (2.37M) | 2.05M | (6.16M) | 28.43M |
| Operating Cash Flow | (40.56M) | (81.38M) | (23.53M) | (11.21M) | (10.8M) |
| Capital Expenditures | (2.02M) | (1.57M) | (59K) | (761K) | (273K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1.05M) | (929K) | (43K) | (726K) | 0 |
| Investing Cash Flow | (2.02M) | (1.57M) | (59K) | (761K) | (943K) |
| Debt Repayment | (3.49M) | (1.5M) | 156K | (816K) | 55K |
| Common Stock Issued | 0 | 0 | 0 | 10M | 34.69M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 124.11M | 618K | 269K | (2M) | (2.64M) |
| Financing Cash Flow | 120.62M | (878K) | 28.91M | 16.04M | 32.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 78.05M | (83.82M) | 5.33M | 4.07M | 20.38M |
| Free Cash Flow | (42.58M) | (82.95M) | (23.59M) | (11.97M) | (11.07M) |
Owlet, Inc.
NYSE:OWLT
Intrinsic Alpha fair value
Locked
Current Price
$3.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.